Trial · NCT04413344
Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease
NCT04413344, Phase 1, Phase 2, Completed, Kyoto University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease. Trials, record NCT04413344. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04413344
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease
- NCT number
- NCT04413344
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 8 participants, actual
- Lead sponsor
- Kyoto University
- Conditions
- Familial Alzheimer Disease (FAD), PSEN1 Mutation
- Interventions
- Bromocriptine Mesilate, Placebos
- First posted
- 2020-06-02
- Last updated
- 2025-08-29
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety (Incidence and severity of adverse events and adverse reactions) | Until Week 50 (end of trial) | to assess safety |
| Primary | Severe impairment battery-Japanese version (SIB-J) | Until Week 20 and 36 | to assess cognitive function |
| Primary | Neuropsychiatric Inventory (NPI) | Until Week 20 and 36 | to assess behavioral and psychiatric symptoms of dementia |
| Secondary | Mental Function Impairment Scale (MENFIS) | Until Week 20 and 36 | to assess cognitive function |
| Secondary | Mini-Mental State Examination-Japanese (MMSE-J) | Until Week 20 and 36 | to assess cognitive function |
| Secondary | Disability Assessment for Dementia (DAD) | Until Week 20 and 36 | to assess activities of daily living |
| Secondary | Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III | Until Week 20 and 36 | to assess motor symptoms and signs |
| Secondary | Apathy Scale | Until Week 20 and 36 | to assess apathy |
| Secondary | Plasma Aβ protein concentration | Until Week 20 and 36 | to assess Aβ protein metabolism |
| Secondary | Plasma NfL protein concentration | Until Week 20 and 36 | to assess neurodegeneration |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34193504 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04413344
GET https://conductscience.org/api/trials/v1/NCT04413344/registered